CN102631342A

CN102631342A - Application of epigallocatechin and pharmaceutical composition of epigallocatechin

Info

Publication number: CN102631342A
Application number: CN2012101294588A
Authority: CN
Inventors: 温尧林; 王锦锦; 刘娜
Original assignee: SUZHOU KAIXIANG BIOTECHNOLOGY CO Ltd
Current assignee: SUZHOU KAIXIANG BIOTECHNOLOGY CO Ltd
Priority date: 2012-04-28
Filing date: 2012-04-28
Publication date: 2012-08-15

Abstract

The invention discloses an application of epigallocatechin and a pharmaceutical composition of epigallocatechin. The epigallocatechin has obvious effect of reducing concentration of blood uric acid and can form a novel potential medicament used for treating hyperuricemia. In the medicament used for treating hyperuricemia, the epigallocatechin is taken as active ingredients used for treating the hyperuricemia, and the epigallocatechin is prepared into various officinal formulations by adopting a conventional method with pharmaceutically acceptable excipient and/or an officinal carrier together.

Description

The purposes of epigallo catechin and pharmaceutical composition thereof

Technical field

The present invention relates to the purposes of epigallo catechin, also relate to and contain the pharmaceutical composition of epigallo catechin as effective ingredient.

Background technology

Gout is a kind of disease due to one group of purine metabolic disturbance, is the uratic chronic deposition of tiny tip-like, and hyperuricemia is its important biochemical basis.The gout clinical manifestation is gouty arthritis and the joint deformity that the crystallization of metabolic arthritis salt causes, lets part, the whole body symptom red, swollen, hot, pain occur, like untimely treatment; Can cause gouty nephritis; Uric acid renal calculus, and sexual hypofunction, multiple complications such as hypertension.

Epigallo catechin (epigallocatechin, EGC), molecular formula: C ₁₅H ₁₄O ₇, molecular weight: 306.27, chemical constitution:

CAS accession number: 970-74-1.

Epigallo catechin (epigallocatechin EGC) is the Polyphenols composition that from green tea, extracts, the epigallo catechin that the triumphant auspicious bio tech ltd in Suzhou extracts from Folium Camelliae sinensis, and purity reaches more than 98%.The character of epigallo catechin and epigallocatechin gallate (EGCG) (epi-gallocatechin3-gallate, EGCG) similar, but antioxidant activity is more lower slightly than EGCG.Have report to show at present, EGC has the skeleton of stimulation and forms, and helps to slow down the aged effect of skeleton.The applicant has carried out a large amount of research, has proved that through experiment epigallo catechin treats the new purposes of hyperuricemia in addition, and the present invention then has been born.

Summary of the invention

First purpose of the present invention provides the activity that epigallo catechin has the treatment hyperuricemia, is used for preparation treatment antihyperuricemic disease drug;

Second purpose of the present invention provides and contains the pharmaceutical composition that epigallo catechin is used as the treatment hyperuricemia of effective ingredient, and this pharmaceutical composition also contains conventional pharmaceutical carrier and/or pharmaceutically acceptable excipient.

This pharmaceutical composition is processed injection, tablet, capsule, aerosol, suppository, membrane, drop pill, externally-applied liniment, controlled release or slow release formulation or nanometer formulation.

The present invention compared with prior art has advantage: prove that through experimentation epigallo catechin has the effect of tangible reduction blood uric acid concentration, can form a kind of novel potential treatment antihyperuricemic disease drug.

Description of drawings

Accompanying drawing 1 is that the uric acid concentration of dose groups, medicine high dose group, positive drug group in matched group, model group, medicine low dose group, the medicine compares sketch map.

The specific embodiment

Below further set forth the present invention.

1, experimental raw:

Epigallo catechin is to be extracted from Folium Camelliae sinensis by the triumphant auspicious bio tech ltd in Suzhou to prepare purity 98%; Also can obtain from the buying of companies such as sigma.

2, laboratory animal:

Kunming mouse, 28 ± 2g, male.

3, medicine configuration:

(epigallocatechin EGC) is dissolved in the pure water, is used for gastric infusion, administration low dosage 15mg/kg, middle dosage 40mg/kg, high dose 60mg/kg, positive drug allopurinol 5mg/kg with the epigallo catechin of purity 98%.

4, experimental technique:

Get 60 of Kunming mouses, be divided into 6 groups (10 every group) at random, be respectively dose groups, medicine low dose group in matched group, model group, positive drug group, medicine high dose group, the medicine.Dose groups, the administration of medicine low dose group difference are 10 days in positive drug group, medicine high dose group, the medicine, every day 1 time.Behind the last administration 1h, except that matched group, all the other each treated animal lumbar injection Oteracil Potassium 300mg/kg cause the mice hyperuricemia, matched group injection solvent.1.5h after, each treated animal is plucked eyeball and is got blood, and 4 ℃ are centrifugal, and 3000rpm*10min uses uricase kit measurement hematuria acid number, carries out group difference property relatively.

Concrete experimental procedure is following:

4.1 kunming mice, adaptability raised for 1 week, then according to body weight divide into groups, labelling and weighing;

4.2 dose groups, the administration of medicine low dose group difference are 10 days in positive drug group, medicine high dose group, the medicine, every day 1 time, the filling stomach time is controlled at 9:00-10:00 in the morning; Matched group, model group give aqueous solvent and irritate stomach;

4.3 behind the last administration 1h, except that matched group, all the other each treated animal lumbar injection Oteracil Potassium 300mg/kg, the concentration of making up a prescription 30mg/ml, injection volume 0.1ml/10g causes the mice hyperuricemia.Formulate inject time and strict execution of every animal of form plan;

4.4 injection back 1.5h uses capillary tube to get blood at mouse orbit, about 0.75ml.Room temperature leaves standstill 1h, and 4 ℃ centrifugal, and 3000rpm*10min gets supernatant;

4.5 use the uricase kit measurement serum uric acid concentration of Shanghai Kehua Bio-engineering Co., Ltd;

4.5.1 get serum as measuring sample;

Establish blank pipe, standard pipe and sample tube 4.5.2 measure, according to form liquid feeding in two steps;

4.5.3 each pipe of mixing, 37 ℃ of water-baths were cooled to room temperature after 5 minutes, in spectrophotometer 550nm wavelength colorimetric, with reagent blank pipe school zero, read the light absorption value of sample tube and standard pipe;

4.5.4 according to light absorption value, calculate the uric acid concentration of sample, uric acid (μ mol/L)=(sample tube absorbance-blank pipe absorbance)/(standard pipe absorbance-blank pipe absorbance) * 590 (standard substance concentration).

5, experimental result:

Referring to Fig. 1, the uric acid level of model group is compared with matched group, and difference has highly significant property meaning (##p＜0.01), shows that the mice hyperuricemia model makes up successfully; Epigallo catechin (epigallocatechin; The uric acid level of low dose group EGC), middle dose groups, high dose group, positive drug group obviously reduces; Compare with model group, difference has significance and highly significant property meaning (* p＜0.05 and * * p＜0.01).

Sum up, from the experiment of epigallo catechin to the mice hyperuricemia model, be not difficult to find out, epigallo catechin has the effect of tangible reduction blood uric acid concentration, can form a kind of novel potential treatment antihyperuricemic disease drug.In treatment antihyperuricemic disease drug, epigallo catechin adopts conventional method to be prepared into various pharmaceutical dosage forms as the active component of treatment hyperuricemia with pharmaceutically acceptable excipient and/or pharmaceutical carrier.

Claims

1. the application of epigallo catechin in preparation treatment antihyperuricemic disease drug.

2. pharmaceutical composition wherein contains epigallo catechin as effective ingredient, and contains conventional pharmaceutical carrier and/or pharmaceutically acceptable excipient.

3. pharmaceutical composition as claimed in claim 2 is processed injection, tablet, capsule, aerosol, suppository, membrane, drop pill, externally-applied liniment, controlled release or slow release formulation or nanometer formulation.